Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNN4 | O15554 | 2/20 | 0.47 |
| ▸ | KIF11 | P52732 | 1/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.39 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.39 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.39 |
| ▸ | CCNE1 | P24864 | 4/20 | 0.38 |
| ▸ | CDK2 | P24941 | 4/20 | 0.38 |
| ▸ | CDK7 | P50613 | 4/20 | 0.38 |
| ▸ | CCNH | P51946 | 4/20 | 0.38 |
| ▸ | CDK4 | P11802 | 3/20 | 0.38 |
| ▸ | CCND1 | P24385 | 3/20 | 0.38 |
| ▸ | CDK1 | P06493 | 2/20 | 0.38 |
| ▸ | CCNB1 | P14635 | 2/20 | 0.38 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | GRIN1 | Q05586 | 4/20 | 0.36 |
| ▸ | GRIN2A | Q12879 | 4/20 | 0.36 |
| ▸ | GRIN2D | O15399 | 3/20 | 0.36 |
| ▸ | GRIN2C | Q14957 | 3/20 | 0.36 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3853041 | 1.00 | KCNN4 (0.47) | KCNN4KIF11SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL3852207 | 0.83 | KCNN4 (0.47) | KCNN4KIF11SLC6A4CCNE1CDK2 | |
| SCHEMBL3854524 | 0.83 | KCNN4 (0.47) | KCNN4KIF11SLC6A4CCNE1CDK2 | |
| SCHEMBL6565005 | 0.83 | KCNN4 (0.47) | KCNN4KIF11SLC6A4CCNE1CDK2 | |
| SCHEMBL3666885 | 0.83 | KCNN4 (0.50) | KCNN4KIF11SLC6A4CCNE1CDK2 | |
| SCHEMBL3862734 | 0.83 | KCNN4 (0.50) | KCNN4KIF11CCNE1CDK2CDK7 | |
| SCHEMBL3862881 | 0.83 | KCNN4 (0.50) | KCNN4KIF11CCNE1CDK2CDK7 | |
| SCHEMBL3853261 | 0.83 | KCNN4 (0.50) | KCNN4KIF11SLC6A4CCNE1CDK2 | |
| SCHEMBL3307096 | 0.83 | KCNN4 (0.50) | KCNN4KIF11SLC6A4CCNE1CDK2 | |
| SCHEMBL4484584 | 0.83 | KCNN4 (0.50) | KCNN4KIF11SLC6A4CCNE1CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8846696-B2 | Purine derivatives | CYCLACEL LIMITED (GB) | 2014-09-30 | — | — | US | disclosed |
| US-8846696-B2 | Purine derivatives | CYCLACEL LIMITED (GB) | 2014-09-30 | — | — | US | disclosed |
| US-8846696-B2 | Purine derivatives | CYCLACEL LIMITED (GB) | 2014-09-30 | — | — | US | disclosed |
| US-20090325983-A1 | NEW PURINE DERIVATIVES | CYCLACEL LIMITED (GB) | 2009-12-31 | — | — | US | disclosed |
| US-20090325983-A1 | NEW PURINE DERIVATIVES | CYCLACEL LIMITED (GB) | 2009-12-31 | — | — | US | disclosed |
| US-20090325983-A1 | NEW PURINE DERIVATIVES | CYCLACEL LIMITED (GB) | 2009-12-31 | — | — | US | disclosed |
| US-7612079-B2 | 2,6,9-substituted purine derivatives and their use in the treatment of proliferative disorders | CYCLACEL LIMITED (GB) | 2009-11-03 | — | — | US | disclosed |
| US-20090270427-A1 | PURINE DERIVATIVES | CYCLACEL LIMITED (GB) | 2009-10-29 | — | — | US | disclosed |
| US-20090270427-A1 | PURINE DERIVATIVES | CYCLACEL LIMITED (GB) | 2009-10-29 | — | — | US | disclosed |
| US-20090270427-A1 | PURINE DERIVATIVES | CYCLACEL LIMITED (GB) | 2009-10-29 | — | — | US | disclosed |
| EP-1534708-B1 | PURINE DERIVATIVES AND THEIR USE AS ANTIPROLIFERATIVE AGENTS | CYCLACEL LTD (GB) | 2006-04-26 | — | — | EP | disclosed |
| US-20050256142-A1 | 4-{9-Isopropyl-6-[(pyridin-3-ylmethyl)-amino]-9H-purin-2-ylamino}-2-methyl-hexan-3-ol;antiproliferative agents; viricides; alopecia; strokes; central nervous system diorders; neurodegenerative diseases; antidiabetic agents; mitosis; cyclin dependent kinase inhibitors; protein kinase inhibitors | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2005-11-17 | — | — | US | disclosed |
| EP-1399446-B1 | 2,6,9-SUBSTITUTED PURINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF PROLIFERATIVE DISORDERS | CYCLACEL LTD (GB) | 2005-08-03 | — | — | EP | disclosed |
| EP-1534708-A2 | PURINE DERIVATIVES AND THEIR USE AS ANTIPROLIFERATIVE AGENTS | Cyclacel Limited (GB) | 2005-06-01 | — | — | EP | disclosed |
| EP-1529047-A2 | NEW PURINE DERIVATIVES | Cyclacel Limited (GB) | 2005-05-11 | — | — | EP | disclosed |
| US-20050009846-A1 | 2,6,9-Substituted purine derivatives and their use in the treatment of proliferative disorders | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2005-01-13 | — | — | US | disclosed |
| EP-1399446-A1 | 2,6,9-SUBSTITUTED PURINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF PROLIFERATIVE DISORDERS | Cyclacel Limited (GB) | 2004-03-24 | — | — | EP | disclosed |
| WO-2004016612-A2 | NEW PURINE DERIVATIVES | CYCLACEL LIMITED (GB) | 2004-02-26 | — | — | WO | disclosed |
| WO-2004016613-A2 | PURINE DERIVATIVES AND THEIR USE AS ANTIPROLIFERATIVE AGENTS | CYCLACEL LIMITED (GB) | 2004-02-26 | — | — | WO | disclosed |
| WO-2003002565-A1 | 2,6,9-SUBSTITUTED PURINE DERIVATIVES AND THEIR USE N THE TREATMENT OF PROLIFERATIVE DISORDERS | CYCLACEL LIMITED (GB) | 2003-01-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090325983-A1 | NEW PURINE DERIVATIVES | C5, CYC1, CCNH | KCNN4 3059/4885KIF11 4675/4885SLC6A4 1764/4885 |
| US-20050256142-A1 | 4-{9-Isopropyl-6-[(pyridin-3-ylmethyl)-amino]-9H-purin-2-ylamino}-2-methyl-hexan-3-ol;antiproliferative agents; viricides; alopecia; strokes; central nervous system diorders; neurodegenerative diseases; antidiabetic agents; mitosis; cyclin dependent kinase inhibitors; protein kinase inhibitors | CDK1, CDK2, CCND1 | KCNN4 2699/4885KIF11 3481/4885SLC6A4 4373/4885 |
| US-20050009846-A1 | 2,6,9-Substituted purine derivatives and their use in the treatment of proliferative disorders | TYMP, PNP, IMPDH1 | KCNN4 2783/4885KIF11 3633/4885SLC6A4 1164/4885 |
| US-20090270427-A1 | PURINE DERIVATIVES | C5, CYC1, CCNH | KCNN4 2947/4885KIF11 4687/4885SLC6A4 1437/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.